SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc is trending as chatter around AI AR smartglasses, potential buyouts, and increased user engagement drive interest. The community is buzzing about the company's potential to compete with tech giants in the AR space, along with speculation on how it might benefit from regulatory changes impacting competitors like TikTok. High options volume and bullish sentiment suggest strong conviction in the stock's near-term prospects.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending due to its rebranding as Solmate and a $300M investment for a Solana-based digital asset treasury, with ARK Invest's involvement further fueling interest. The community is discussing the potential for significant growth, drawing comparisons to other crypto treasury stocks, while also weighing the risks of dilution.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

After initially rising on better-than-expected earnings, $FDX is now trending lower as investors react to cautious commentary and a weaker outlook due to global trade uncertainty. The community is actively debating the impact of tariffs and potential downgrades, with some anticipating a continued decline. Despite solid Q4 results, the lack of full-year guidance is fueling concerns about future performance, sparking discussions around potential buying opportunities or further downside risk.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as analysts raise price targets ahead of earnings, citing strong AI-driven demand and tight memory supply. Community members are actively discussing whether to take profits or hold through earnings, with some pointing to the stock's overbought conditions and potential for a pullback. The stock's strong performance is also drawing comparisons to past market trends and other high-growth tech companies.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Recent conversations around Disney ($DIS) are centered on the suspension of Jimmy Kimmel's show and potential boycotts, sparking debates about free speech and political polarization. Community viewpoints are divided, with some celebrating the decision and others criticizing it as a concession to political pressure. The broader context involves Disney navigating streaming profitability, balancing content strategy with political sensitivities, and facing challenges in linear TV.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Recent discussions around $DJT are centered on potential First Amendment issues, particularly regarding media criticism and censorship. The community is debating the implications of actions taken against media figures and networks, with some viewing them as attacks on free speech. The stock is also caught in broader political debates, influencing its volatile nature.

FatPipe, Inc. engages in the development of software-defined wide area network (SD-WAN) solutions for organizations, including enterprises, communication service providers, security service providers, government organizations, and other middle-market companies. Its products include WARP, MPVPN, SD-WAN, Fatpipe Orchestrator, Next Gen Firewall, 5G and LTE, FatPipe Total Security 360, SASE, SIEM, EnterpriseView, and Cloud Connect. The company was founded by Ragula Bhaskar and Sanchaita Datta on October 14, 2010 and is headquartered in Salt Lake City, UT.

Fatpipe Inc.

FatPipe, Inc. Common Stock

FATN is trending due to increased attention on its low float and potential for a short squeeze, with community members actively discussing potential breakouts and accumulation patterns. The stock's recent IPO and solid fundamentals are also contributing to the heightened interest, as traders anticipate significant price movement with increased volume or news catalysts. Some investors believe the company could be an acquisition target.

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Imunon Inc

IMNN is trending due to ongoing discussions about its Phase 3 trial for ovarian cancer treatment, with community members highlighting the potential of the TheraPlas technology. Some investors express optimism, citing successful Phase 2 data and a relatively low market cap, while others worry about potential dilution and the company's history of reverse stock splits. The stock's volatile price action and recent news about Nasdaq compliance are also fueling the conversation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors digest news and commentary from recent conferences, with community chatter focusing on production timelines for the R2, potential partnerships, and the company's overall financial health. Discussions also revolve around Rivian's long-term viability in a competitive EV market and the impact of potential government incentives.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

AlphaVest Acquisition Corp (ATMV) is trending due to significant pre-market and intraday price volatility, triggering multiple trading halts. Community discussions revolve around the stock's momentum, potential for further gains, and the risks associated with its volatile behavior, with some speculating about news pending or a potential merger agreement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of -23.08% and -20.91%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?

KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.

KalVista Pharmaceuticals, Inc. (KALV) on Monday said that the U.S. Food and Drug Administration (FDA) has approved its drug Ekterly for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older.<a href="https://stocktwits.com/symbol/KALV">KalVista</a>’s shares were up over 17% in pre-market trading.Hereditary angioedema (HAE) is a rare genetic disease caused by deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected.Ekterly is the first and only oral on-demand treatment for HAE, KalVista <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-approval-ekterlyr">said</a>, setting it apart from other on-demand HAE treatment options approved in the U.S., which require intravenous or subcutaneous administration.Even with the use of long-term prophylaxis as a preventative therapy, most people living with HAE continue to have unpredictable attacks and require on-demand access to medication, the company added.KalVista will launch Ekterly in the U.S. immediately, and physicians can begin writing prescriptions on Monday.The approval was based on results from a late-stage study in 136 patients, showing that Ekterly achieved significantly faster symptom relief, a reduction in attack severity, and an increase in attack resolution compared to the placebo. The results also showed that the drug was well-tolerated, with a safety profile similar to that of the placebo.A later study also showed that Ekterly enabled patients to treat attacks in a median of 10 minutes following onset.On Stocktwits, retail sentiment around KalVista jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_8_56_04_AM_png_8e1123c17a.webp" alt="KALV's Sentiment Meter and Message Volume as of 8:55 a.m. ET on July 7, 2025 | Source: Stocktwits" width="626" height="67"><figcaption>KALV's Sentiment Meter and Message Volume as of 8:55 a.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the stock hitting as high as $50 upon the news.<stembedurl>https://stocktwits.com/fzriderz/message/620039415</stembedurl>KALV stock is up by over 41% this year and down by about 2% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/shell-signals-earnings-dip-in-trading-in-q2-but-refining-margin-to-improve/chFthjLR5PR">Shell Signals Earnings Dip In Trading In Q2, But Refining Margin To Improve</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated

Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous or subcutaneous administration. 

Equity

Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous or subcutaneous administration. 


KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: TD Cowen 45th Annual Health Care...

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy...

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology...

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVistas board of directors granted fifty-two newly-hired employees inducement options to purchase...

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japans Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVistas board of directors granted nine newly-hired employees inducement options to purchase an...

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

KALV
KalVista Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KALV News

KALV KalVista Pharmaceuticals Inc